Rohypnol Imports To Be Banned In USA

18 March 1996

The USA has banned the import of Hoffmann-La Roche's sedative drug Rohypnol (flunitrazepam) and the Drug Enforcement Agency will reclassify it as a Schedule 1 drug with no accepted medical use. The product has been a cause of concern in the USA for some time, and has allegedly become the abused drug of choice in some US states.

The US Food and Drug Administration has said that the drug has no legitimate need in the USA that is not already met by legal and approved drugs. A sedative around 10 times more potent than diazepam, it has been linked with "date rape" cases, according to the US Treasury Department. Treasury Secretary Robert Rubin noted that Rohypnol has been gaining popularity in the south and southwest states, where it is commonly used a secondary drug to alcohol and marijuana.

Personal-Use Import Loophole Closed The so-called "roofies" are manufactured overseas and used legally in around 60 countries for insomnia; until the ban, US travelers could import a three-month supply for personal use. The Customs Service will now seize any amount of the drug brought in by travelers, in commercial shipments or by mail.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight